England: HTA Body NICE Makes Big RWE Push

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

England’s health technology appraisal institute, NICE, has published its real-world evidence framework.

Touch the future,Interface technology, the future of user experience.
NICE launches RWE Framework

With its newly published real-world evidence (RWE) framework, NICE, England’s health technology appraisal (HTA) institute, is making “a real push into real-world data in a big way,” Sam Roberts, NICE’s chief executive, said last week at an online event to launch the initiative. The framework, published on 23 June, is intended to be a “living document” that will broaden overtime according to need.

With respect to RWE, NICE is aware that a “step change is needed for the future,” said Roberts, pointing to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Real-World Evidence

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 
• By Eliza Slawther

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

EMA Advances Use Of Real-World Data By HTAs And Payers

 
• By Vibha Sharma

Results from the first pilot real-world evidence study commissioned by the European Medicines Agency to help HTA bodies and payers characterize patients with multiple myeloma have drawn positive feedback.

EU Ocaliva Withdrawal Recommendation Based On ‘Flawed’ Studies

 
• By Francesca Bruce

Overreliance on “problematic” trials while overlooking the value of real-world evidence could affect the development of other rare disease treatments, according to Advanz’s CEO.

More from Clinical Trials

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By Sue Sutter

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 
• By Francesca Bruce

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

US FDA’s MIDD Program Could Expand Beyond Quarterly Requests, But Needs Resources

 
• By Derrick Gingery

An FDA official said the agency is considering allowing MIDD meeting requests to be submitted more often, but must have a plan to deal with the likely increased demand.